TScan Therapeutics, Inc. Common Stock
TCRXTScan Therapeutics, Inc. (TCRX) is a biotechnology company focused on developing adoptive T cell therapies for cancer treatment. Utilizing its proprietary TCR-T platform, TScan aims to engineer T cells that target specific tumor-associated antigens, with the goal of creating personalized and effective immunotherapies for solid tumors. Founded to advance T cell-based cancer treatments, TScan combines advanced science with innovative technology to address unmet needs in oncology.
Company News
TScan Therapeutics reported positive results from Cohort C of its Phase 1 ALLOHA study of TSC-101, a TCR-engineered T cell therapy for hematologic malignancies. 11 of 14 patients achieved complete donor chimerism within three weeks of the first infusion, with all 5 patients assessed after a second infusion showing complete chimerism. The commerci...
TScan Therapeutics reported Q1 2026 financial results with net loss of $28.7 million and revenue of $1.0 million. The company announced multiple clinical milestones including early data from Cohort C of its Phase 1 ALLOHA trial expected in Q2 2026, planned Phase 3 initiation of TSC-101 in Q2 2026, and Phase 1 studies of TSC-102-A01 and TSC-102-A0...
TScan Therapeutics, a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, announced participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company reported completion of enrollment in Cohort C of its Phase 1 ALLOHAâ„¢ trial using a commercial-ready manufacturing pr...
TScan Therapeutics completed enrollment in Cohort C of its Phase 1 ALLOHAâ„¢ trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for TSC-102-A01 and TSC-102-A03 candidates targeting CD45 for patients with HLA types A*01:01 and A*03:01. The company plans to share safety and chim...
TScan Therapeutics reported promising results from its Phase 1 trial of TSC-101 for hematologic malignancies, showing improved relapse-free survival and no dose-limiting toxicities in patients undergoing bone marrow transplantation.
